Nerve damage is slow to heal, and the search for anything that speeds it up runs hot. Hyperbaric oxygen therapy (HBOT) keeps coming up in that search, sold by some clinics as a way to "regrow" damaged nerves. This atlas walks through what the science actually shows for nerve injury and regeneration, where the evidence is real, where it is thin, and where the marketing has gotten far ahead of the data.
Nerve regeneration is the headline use here, but it is not an FDA-cleared or Undersea and Hyperbaric Medical Society (UHMS) approved indication on its own. That distinction matters. It means almost everything below is investigational or off-label, even when the underlying biology looks promising.
What "Nerve Damage" Actually Covers
"Nerve damage" is a broad bucket, and HBOT's evidence differs a lot depending on which kind you mean. Lumping them together is how clinics oversell it.
The main categories:
- Peripheral nerve injury (PNI) — a cut, crush, or stretch to a nerve in an arm, hand, or leg. Think a deep laceration that severs the ulnar nerve, or a surgical injury.
- Diabetic peripheral neuropathy (DPN) — nerve damage from years of high blood sugar, usually starting in the feet. This is a metabolic and vascular problem, not a single trauma.
- Central nervous system injury — the brain and spinal cord. Stroke, traumatic brain injury (TBI), and spinal cord injury (SCI) sit here.
- Cranial nerve problems — Bell's palsy (facial nerve) and sudden hearing loss (auditory nerve) are the common ones.
These tissues heal differently. Peripheral nerves can regenerate, slowly, about a millimeter a day. Central nerves in the brain and spinal cord mostly do not regenerate at all in adults. So a therapy that helps a crushed wrist nerve will not necessarily do anything for a spinal cord. Keep that split in mind for the rest of this piece.
The Mechanism: Why Oxygen Might Help a Healing Nerve
The biological rationale for HBOT in nerve repair is reasonable, and it is worth understanding because it is also where clinics tend to overreach.
A damaged nerve and the tissue around it become hypoxic, meaning starved of oxygen. Swelling, broken blood vessels, and inflammation choke off the supply right when the nerve needs energy to rebuild. HBOT puts you in a sealed chamber, raises the pressure above sea level, and has you breathe near-100% oxygen. Under pressure, far more oxygen dissolves directly into the blood plasma, so it can reach tissue that injured capillaries can no longer serve well.
From there, several plausible effects follow:
- Less swelling. High oxygen levels cause small blood vessels to constrict slightly, which can reduce edema and the pressure squeezing a nerve.
- Angiogenesis. Repeated sessions create an oxygen swing that signals the body to grow new blood vessels, restoring the blood supply a regenerating nerve depends on.
- Schwann cell support and remyelination. Schwann cells are the repair crew of peripheral nerves. Lab studies suggest better oxygenation supports their activity and the rebuilding of the myelin sheath that insulates nerves.
- Lower oxidative stress in reperfusion. Counterintuitively, controlled hyperoxia can blunt the burst of damaging free radicals that hits tissue when blood flow returns.
A 2024 review in the International Journal of Molecular Sciences mapped this out and reached an honest conclusion: oxygen has both helpful and harmful roles in nerve repair, the timing and dose matter enormously, and "HBOT seems to have a beneficial effect on functional recovery after peripheral nerve injury, but the results are mixed" (PMID 38396709).
That same review makes a subtle point worth pausing on. Oxygen is not simply "more is better" for a nerve. Too little oxygen (hypoxia) stalls healing, but a brief, controlled period of low oxygen actually triggers some of the growth signals that drive repair. Too much oxygen at the wrong moment floods tissue with reactive free radicals that can damage the very cells you are trying to save. The therapeutic window is narrow, and nobody has nailed down the ideal pressure, session length, or number of treatments for nerve injury. That uncertainty is a recurring theme in this field.
So this is the key tension. A good mechanism is not the same as a proven treatment. The body of human evidence has to carry that weight, and for nerves it is uneven. Plenty of therapies have a tidy biological story and still fail when tested properly in people. Oxygen's effect on nerves is plausible, but plausibility is the starting line, not the finish.
The Evidence, Graded Honestly
Here is the core of the atlas. The grades below reflect study quality and consistency, not hope.
| Nerve condition | Best available evidence | Honest grade | What it means |
|---|---|---|---|
| Diabetic peripheral neuropathy (DPN) | 14-RCT meta-analysis (2024), large effect on nerve conduction | Moderate, but flawed | Promising signal, weakened by single-country trials and weak blinding |
| Peripheral nerve injury (trauma/surgery) | Scoping review + small prospective studies | Low | Mostly animal data and uncontrolled human reports; positive but unproven |
| Spinal cord injury | RCT meta-analysis (2021), small trials | Very low | Heterogeneous, low-quality; no firm conclusion |
| Bell's palsy (facial nerve) | One older blinded trial; Cochrane review | Very low | Single trial hints at benefit; not enough to recommend |
| Stroke / TBI (central) | Mixed RCTs, sham-controlled trials | Low and contested | Some positive trials, some null; far from settled |
Diabetic Peripheral Neuropathy: The Strongest Case (With Caveats)
DPN has the most human data, and on paper it looks good. A 2024 systematic review and meta-analysis in Medicine pooled 14 randomized trials covering 675 HBOT patients and 648 standard-therapy patients. HBOT was tied to a much higher "effective" rate (odds ratio 8.06, 95% CI 4.49 to 14.47) and to faster nerve conduction across several nerves. For the median nerve, motor conduction velocity improved by a mean of 5.53 m/s (95% CI 4.13 to 6.93); sensory conduction and the ulnar, peroneal, and tibial nerves all moved in the same direction (PMID 39252242).
Those are real, measurable nerve-function gains, not just symptom surveys. So why only a "moderate" grade?
Because the same authors flagged serious problems. Every one of the 14 trials was run in China, the randomization and blinding methods were poorly described, and there was significant statistical heterogeneity and signs of publication bias. When all the studies share the same geographic and methodological blind spots, an enormous odds ratio like 8.06 should make you cautious, not confident. The signal is consistent enough to take seriously and study further. It is not strong enough to call HBOT a proven DPN treatment. For more on this specific use, see our deeper look at HBOT for diabetic peripheral neuropathy.
Peripheral Nerve Injury From Trauma or Surgery: Promising in Animals, Thin in Humans
This is the use that clinic websites mean when they say "nerve regeneration." The honest evidence grade is low.
The most useful summary is a 2023 scoping review in Regional Anesthesia & Pain Medicine that looked at HBOT for nerve injury around surgery. HBOT was reported as beneficial in 88% of included studies, with no major adverse events (PMID 36418044). That sounds impressive until you read the fine print: most of those studies were in animals, the human studies were few and often uncontrolled, and the HBOT protocols were all over the map in timing and dose. The authors explicitly called for proper randomized trials, which is researcher-speak for "we don't actually know yet."
The foundational animal and lab work goes back decades, including a 2006 review in Plastic and Reconstructive Surgery on how hyperbaric oxygen affects peripheral nerves (PMID 16874201). In rats with crushed or severed nerves, HBOT has been linked to faster return of function, more myelin, and better blood vessel growth at the repair site. That is genuinely interesting biology.
The problem is the jump from rat to human. A small human series, such as a prospective study of patients after surgical repair of severed hand nerves (ulnar and median) followed for a year with nerve-conduction testing, reported faster recovery when HBOT was added to standard repair (PubMed search: HBOT peripheral nerve recovery upper extremity). But these studies are small, usually not blinded, and prone to bias. People who choose extra treatment tend to be more motivated and healthier overall, which can fake a treatment effect. Without a sham-controlled trial, you cannot separate the oxygen from the placebo and selection effects.
If a clinic shows you a glossy claim about regrowing nerves, this is the evidence base behind it: strong animal work, a handful of encouraging but weak human studies, and no large blinded trial. That is not nothing. It is also not proof.
Spinal Cord Injury: A Hard Problem, Weak Data
Spinal cord injury is one of the most devastating nerve injuries, so the temptation to try anything is understandable. The evidence does not support HBOT here.
A 2021 systematic review and meta-analysis of randomized trials in the Journal of Back and Musculoskeletal Rehabilitation pooled 11 small trials (875 patients) and did report improvements in motor and sensory scores with HBOT, but the included studies were few and low-quality with extreme statistical heterogeneity, so the authors only concluded HBOT "may" help and called for larger high-quality RCTs (PMID 33935063). Animal studies are more encouraging, but the gap between a rodent spinal cord and a human one is wide, and adult central nerves largely don't regenerate. Grade: very low. Treat any clinic selling HBOT as a spinal cord "regeneration" therapy with deep skepticism.
Bell's Palsy and Cranial Nerves
Bell's palsy is sudden facial weakness from inflammation of the facial nerve. Most people recover on their own, which makes it tricky to test any treatment.
A Cochrane review found only one usable trial, in which a hyperbaric oxygen group recovered normal facial movement more often than a prednisone group (95% versus 76%). But the review rated the evidence as very low quality and stopped short of recommending HBOT (Cochrane CD007288). One old trial is a hint, not a verdict. We cover this in detail in HBOT for Bell's Palsy recovery research.
Sudden sensorineural hearing loss, which involves the auditory nerve, is actually a UHMS-approved indication and has better support, so it is a different story from the rest of this list.
Brain and Central Nervous System Injury
Stroke and traumatic brain injury get lumped into "nerve regeneration" marketing too, so they deserve a clear word. The central nervous system is the hardest case, and the evidence is both mixed and hotly debated.
Some randomized and sham-controlled trials of HBOT for chronic stroke and post-concussion symptoms have reported cognitive gains; others have found no benefit over a convincing sham. The trials differ in patient type, timing after injury, pressure, and how they built the placebo arm, which makes them hard to pool. The reasonable read in 2026 is that HBOT for brain injury remains unproven and contested, with enthusiasts and skeptics each able to cite real studies. It is not the slam dunk some clinics imply. We dig into this in HBOT for traumatic brain injury: the 2026 evidence atlas. The bottom line for this article: do not assume a brain or spinal cord nerve can be "regrown" the way a peripheral nerve sometimes can.
Where Nerve Regeneration Sits Officially: Off-Label
This is the part clinics rarely lead with. Nerve regeneration is not on the official list of HBOT indications.
The UHMS and Medicare recognize roughly 14 to 15 conditions where HBOT is established treatment. That list includes things like diabetic foot ulcers, radiation tissue injury, carbon monoxide poisoning, and sudden hearing loss. It does not include "nerve regeneration," diabetic neuropathy, peripheral nerve injury, spinal cord injury, or Bell's palsy (UHMS Clinical Practice Guidelines; UCLA Health HBOT indications).
What that means in practice:
- Insurance almost never covers it for nerve regeneration. You will likely pay out of pocket, often $200 to $500 per session, with protocols running 20 to 60 sessions.
- The clinic is using it off-label. Off-label use can be legitimate medicine, but it shifts the burden onto you to judge the evidence.
- A nerve-related FDA-approved use exists nearby but is not the same. HBOT is approved for diabetic foot ulcers, a wound problem, not for the neuropathy that often comes with diabetes. Clinics sometimes blur that line. See HBOT for diabetic foot ulcer for the approved use.
Run the math before you commit. At $300 a session, a 40-session course is $12,000, and there is no guarantee of benefit for an unproven use. That is real money against low-to-moderate evidence. Compare that to standard care for the same conditions, which is usually covered and has decades of proof behind it. The opportunity cost is not just the dollars but the weeks of your time and the risk of delaying treatments that actually work.
One more wrinkle: "hard" hospital-grade chambers (used for approved indications at higher pressure) differ from the lower-pressure "soft" or "mild" chambers marketed for wellness. Much of the lab rationale for nerve effects rests on the higher pressures hard chambers reach. A mild chamber at low pressure may not deliver the same dose of oxygen the studies used, which means the (already thin) evidence may not transfer to a soft-shell setup at all. If you are considering this, know which type of chamber the clinic uses and at what pressure.
Comparing HBOT to the Alternatives
HBOT is rarely the first or only option for nerve damage. Honest comparison matters.
| Approach | Evidence for nerve recovery | Typical cost | Role |
|---|---|---|---|
| Surgical nerve repair | Strong for severed/compressed nerves | Covered by insurance | Standard of care for structural injury |
| Physical/occupational therapy | Strong supporting evidence | Usually covered | Backbone of functional recovery |
| Blood sugar control (for DPN) | Strong | Low | The proven foundation for diabetic neuropathy |
| Medications (gabapentin, duloxetine) | Moderate for pain, not regeneration | Low, often covered | Symptom control, not nerve repair |
| HBOT | Low to moderate, condition-dependent | High, rarely covered | Investigational add-on |
| Stem cell / "regenerative" injections | Very low / experimental | Very high | Mostly unproven, often unregulated |
The pattern: the boring, proven options come first. For a severed nerve, surgery and rehab do the heavy lifting. For diabetic neuropathy, controlling blood sugar is the foundation; HBOT might be an add-on, not a substitute. If a clinic positions HBOT as a replacement for surgery or glucose control, that's a red flag. For a wider menu, see best alternatives to hyperbaric oxygen therapy.
Safety: Generally Low Risk, Not Zero
HBOT is reasonably safe in proper hands, but it is a real medical treatment with real side effects, not a spa add-on.
A 2023 systematic review and meta-analysis in Frontiers in Medicine (24 RCTs, 1,497 patients) found the HBOT group had more adverse effects than controls (30.11% versus 10.43%). The risk climbed with longer courses (more than 10 sessions) and higher chamber pressures (above 2.0 ATA). Most events were minor, with ear discomfort the single most common (PMID 37275378).
The main risks to know:
- Ear and sinus barotrauma — the most common problem, from pressure changes. Often managed by learning to clear your ears.
- Temporary nearsightedness (myopia) — vision can blur over a long course and usually reverses within weeks of stopping. Common with extended protocols.
- Oxygen toxicity seizure — rare (roughly 1 in 2,000 to 1 in 10,000 sessions), brief, and generally without lasting harm.
- Lung and chamber concerns — people with certain lung conditions, an untreated collapsed lung, or specific medications need screening first.
For nerve damage protocols, which can run many sessions, the myopia and ear issues are the realistic ones to plan around. None of this makes HBOT dangerous in a credentialed center. It does mean the cost-benefit math should clear a real bar, and for unproven nerve uses that bar is higher.
Who This Is and Isn't For
A sober read on candidacy:
Might reasonably consider it (with eyes open):
- People with diabetic peripheral neuropathy who have already maximized blood sugar control and standard care, and who understand the evidence is moderate and the cost is theirs.
- Patients after surgical repair of a traumatic nerve injury, as an investigational add-on, ideally inside a clinical trial.
Should be skeptical:
- Anyone told HBOT will "regenerate" a spinal cord or reverse a central nervous system injury.
- People being steered away from proven care (surgery, rehab, glucose control) toward HBOT as a replacement.
- Anyone on a fixed budget facing a $5,000-plus out-of-pocket course for a low-evidence use.
The single best move before paying for anything: ask the clinic what specific peer-reviewed human evidence supports HBOT for your exact condition, and whether your use is FDA-approved or off-label. A trustworthy provider will tell you it's off-label and walk through the limits. To understand the science underneath all of this, our complete guide to how HBOT works is a good next read.
Frequently Asked Questions
Can HBOT actually regenerate damaged nerves?
It may support the natural repair process for peripheral nerves, which can regenerate on their own slowly. The biology is plausible and animal studies are encouraging, but solid human evidence is limited. For central nerves in the brain and spinal cord, which mostly do not regenerate in adults, there is no good evidence HBOT regrows them. "Regeneration" is the most overhyped claim in this space.
Is HBOT for nerve damage covered by insurance?
Almost never, when the target is nerve regeneration or neuropathy. Those uses are off-label and not on the UHMS or Medicare approved list. Insurance does cover HBOT for related approved conditions like diabetic foot ulcers, but that is a wound indication, not a nerve-repair one. Expect to pay out of pocket, often thousands of dollars for a full course.
How many HBOT sessions would nerve treatment take?
There is no standardized protocol because the use is investigational. Clinics commonly run 20 to 60 sessions, each 60 to 90 minutes, several times a week. The lack of a proven protocol is itself a sign the evidence is immature; established HBOT indications have defined session counts and pressures, and nerve regeneration does not.
Which nerve condition has the best HBOT evidence?
Diabetic peripheral neuropathy has the most human data, including a 14-trial meta-analysis showing improved nerve conduction. But that evidence is weakened by quality problems, so it rates as moderate at best. Traumatic peripheral nerve injury and spinal cord injury have much weaker, mostly animal-based or low-quality human evidence.
Is HBOT safe for someone with nerve damage?
For most people, yes, it is low risk in a proper clinical setting. The common side effects are ear pressure problems and temporary blurry vision over a long course, with rare oxygen-related seizures. The bigger issue is usually not safety but value: paying a high price for a use the evidence does not yet strongly support.
This article is for general information only and is not medical advice. Talk with a qualified healthcare provider before starting hyperbaric oxygen therapy or making any decisions about treating nerve damage.